Overview

Aurograb and Vancomycin in MRSA Infection

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The study hypothesis is that the addition of Aurograb to standard vancomycin therapy will improve outcome in MRSA infection.
Phase:
Phase 3
Details
Lead Sponsor:
NeuTec Pharma
Treatments:
Vancomycin